Back

Heterogeneous effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular events among people with type 2 diabetes: an application of machine learning to target trial emulation

1 September 2024 (08:15 - 08:25)
Organised by: Logo
Congress Presentation Part of: The broad spectrum of cardiovascular risk Diabetes and the Heart ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Yuichiro Mori

Kyoto University Graduate School of Medicine, Kyoto (Japan)

5 More presentations in this session

Presentation thumbnail
Red cell distribution width as a predictor of cardiovascular events in high-risk patients with statin intolerance: post-hoc analysis of the CLEAR Outcomes trial
Doctor P. Moriarty (Kansas City, US)
Abstract Slides Video
Presentation thumbnail
High physical activity relates to higher risk of incident carotid plaque components
Mr L. Zuo (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Estimation of individual lifetime cardiovascular disease risk and treatment benefit in patients with established atherosclerotic cardiovascular disease: the updated SMART-REACH2 model
Mr J. Holtrop (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Sex-differences in prescription patterns of secondary prevention pharmacotherapy in patients with acute myocardial infarction: a 20-year perspective
Professor H. Rickli (St. Gallen, CH)
Abstract Slides Video
Presentation thumbnail
Association of insulin resistance with cardiovascular disease and all-cause mortality in type 1 diabetes mellitus: systematic review and meta-analysis
Doctor R. Sun (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
The broad spectrum of cardiovascular risk
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Heterogeneous effectiveness of SGLT2 inhibitors for individuals without established CVDs: A population based study with machine learning approach
thumbnail
Congress Presentation
Sodium-Glucose Co-Transporter 2 inhibitors and cardiovascular outcomes: a trial-similar population vs. a broad population
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources